Last paragraph pretty much sums it up......
Apr 01
Full year 2022 earnings released: CA$0.15 loss per share (vs CA$0.059 loss in FY 2021)
Full year 2022 results:
- CA$0.15 loss per share (further deteriorated from CA$0.059 loss in FY 2021).
- Revenue: CA$94.5m (up 13% from FY 2021).
- Net loss: CA$130.3m (loss widened 184% from FY 2021).
Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Pharmaceuticals industry in Canada.
Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 61% per year, which means it is significantly lagging earnings.